FY2028 Earnings Estimate for AbbVie Issued By William Blair

AbbVie Inc. (NYSE:ABBV) – William Blair issued their FY2028 EPS estimates for shares of AbbVie in a note issued to investors on Monday, June 30th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of $16.15 for the year. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

Other research analysts have also issued research reports about the stock. Bank of America raised their price target on shares of AbbVie to $204.00 and gave the stock a “hold” rating in a report on Monday, June 9th. Citigroup raised their price target on shares of AbbVie to $205.00 and gave the stock a “hold” rating in a report on Wednesday, June 11th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 22nd. Evercore ISI raised their price target on shares of AbbVie from $204.00 to $205.00 and gave the stock an “outperform” rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $194.00 price target on shares of AbbVie in a report on Tuesday, April 8th. Eight equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $211.29.

AbbVie Stock Down 0.7%

AbbVie stock opened at $189.50 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. AbbVie has a 52-week low of $163.63 and a 52-week high of $218.66. The firm has a 50 day moving average price of $187.37 and a two-hundred day moving average price of $188.46. The firm has a market cap of $334.73 billion, a price-to-earnings ratio of 80.64, a PEG ratio of 1.26 and a beta of 0.48.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same period last year, the company earned $2.31 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year.

Institutional Trading of AbbVie

Hedge funds and other institutional investors have recently bought and sold shares of the business. TD Capital Management LLC increased its stake in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Abound Financial LLC bought a new stake in shares of AbbVie in the 1st quarter worth $30,000. EnRich Financial Partners LLC grew its stake in shares of AbbVie by 196.4% in the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. Promus Capital LLC bought a new stake in shares of AbbVie in the 4th quarter worth $30,000. Finally, Cypress Capital Management LLC WY bought a new stake in shares of AbbVie in the 1st quarter worth $35,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.46%. AbbVie’s dividend payout ratio (DPR) is presently 279.15%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.